Successful haploidentical hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria with severe pancytopenia developed after long-term aplastic anemia treatment.

Sakurai, Kazuki; Saito, Kei; Hatta, Shunsuke; Katsuoka, Yuna; Meguro, Kuniaki; Yokoyama, Hisayuki; Izumi, Toru

Sakurai, Kazuki; Saito, Kei; Hatta, Shunsuke; Katsuoka, Yuna; Meguro, Kuniaki; Yokoyama, Hisayuki; Izumi, Toru.

Afiliação

Sakurai K; Department of Hematology National Hospital Organization Sendai Medical Center Sendai Japan.
Saito K; Department of Hematology Tohoku University Hospital Sendai Japan.
Hatta S; Department of Hematology National Hospital Organization Sendai Medical Center Sendai Japan.
Katsuoka Y; Department of Hematology National Hospital Organization Sendai Medical Center Sendai Japan.
Meguro K; Department of Hematology National Hospital Organization Sendai Medical Center Sendai Japan.
Yokoyama H; Department of Hematology National Hospital Organization Sendai Medical Center Sendai Japan.
Izumi T; Department of Hematology National Hospital Organization Sendai Medical Center Sendai Japan.

Clin Case Rep ; 12(5): e8832, 2024 May.

Article em En | MEDLINE | ID: mdl-38681032

ABSTRACT

ABSTRACT

Haploidentical hematopoietic stem cell transplantation (HSCT) with posttransplant cyclophosphamide is an alternative treatment for aplastic anemia-paroxysmal nocturnal hemoglobinuria (PNH) syndrome with poor prognostic factors. Ravulizumab treatment for PNH before HSCT might have a beneficial effect.

Palavras-chave

alternative donor; aplastic anemiaparoxysmal nocturnal hemoglobinuria syndrome; haploidentical hematopoietic stem cell transplantation; posttransplant cyclophosphamide; ravulizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google